logo
Plus   Neg
Share
Email

Dr. Reddy's Launches Deferasirox Tablets In U.S.

Dr. Reddy's Laboratories Ltd. (RDY,DRREDDY) announced Friday the launch of Deferasirox Film-Coated Tablets, 90 mg and 360 mg. It is a therapeutically equivalent generic version of Jadenu (deferasirox) Film-Coated Tablets, 90 mg, 180 mg, and 360 mg, approved by the U.S. Food and Drug Administration.

The Jadenu brand had U.S. sales of approximately $470 million for the most recent twelve months ended in September 2019.

The company also announced the launch of Deferasirox Tablets for Oral Suspension, a therapeutically equivalent generic version of Exjade (deferasirox) Tablets for Oral Suspension, approved by the FDA.

The Exjade brand had U.S. sales of approximately $113 million in a year ended September 2019.

Dr. Reddy's Deferasirox Tablets for Oral Suspension, are available in 125 mg, 250 mg, and 500 mg dosage strengths in bottle count sizes of 30.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The former chief executive officer of Hertz Global Holdings, Mark Frissora, agreed to pay about $2.2 million to settle the U.S. Securities and Exchange Commission's claims that he played a key role in causing the now-bankrupt car-rental company to file inaccurate financial statements in 2013. Daimler AG, the maker of Mercedes-Benz cars, said Thursday that it has agreed to pay more than $2.2 billion to settle U.S. claims over emissions from its diesel vehicles. A new class-action lawsuit filed against Facebook accuses the company's photo and video-sharing app Instagram of illegally collecting biometric data of as many as 100 million users without their consent, according to reports. The lawsuit filed in a state court in California, alleges that Instagram uses its photo-tagging technology to create a database of users' facial features.
Follow RTT